Technical Data
M2690-01
MCAF, Recombinant, Human (MCP-1, Macrophage/Monocyte Chemotactic and Activating Factor)
5ug
20ug
20ug
|
Technical Data |
|
M2690-01 |
MCAF, Recombinant, Human (MCP-1, Macrophage/Monocyte Chemotactic and Activating Factor) |
5ug 20ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: RT |
|
Recombinant Human MCP-1 also known as Monocyte Chemotactic and Activating Factor (MCAF) is a non-glycosylated, Polypeptide chain containing 76 amino acids and having a molecular mass of 8607 Dalton. Sequence: The sequence of the first five N-terminal amino acids was determined and was found to be Gln-Pro-Asp-Ala-Ile. Dimers and Aggregates: 1% as determined by silver-stained SDS-PAGE gel analysis. Biological Activity: MCP-1 is fully biologically active when compared to standard. The specific activity as determined by the ability of MCP-1 to chemoattract human Monocytes using a concentration of 5-20ng/ml. Endotoxin: 0.1ng/ug (IEU/ug) of rHuMCP-1. Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm. 2. Analysis by RP-HPLC, using a standard solution of MCP-1 as a Reference Standard. Reconstitution: Reconstitute the lyophilized rHuMCP-1 in sterile 18M -cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions. Storage and Stability: Lyophilized powder may be stored at 4°C for short-term only. Reconstitute to nominal volume by adding sterile dH2O and store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. |
Source: E. coli Purity: 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Concentration: ~0.1mg/ml Form: Supplied as a lyophilized powder. No additives. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis. Schirmer SH, Buschmann IR, Hoefer IE, Bode C, Cardiovasc Res 2004 Nov 1;64(2):356-64 2. Negative association between circulating total homocysteine and proinflammatory chemokines MCP-1 and RANTES in prepubertal lean, but not in obese, children. Economou EV, Malamitsi-Puchner AV, Kouskouni EE, Creatsas G, J Cardiovasc Pharmacol 2004 Sep;44(3):310-5 3. MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. Fenoglio C, Galimberti D, Guidi I, Mariani C, Neurobiol Aging 2004 Oct;25(9):1169-73 4. Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism and risk of Alzheimer's disease in Italians. Pola R, Flex A, Proia AS, Pecorini G, Exp Gerontol 2004 Aug;39(8):1249-52 5. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients. Chang L, Ernst T, Conant K, Antivir Ther 2004 Jun;9(3):431-40 6. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Hiraoka M, Nitta N, Shimokado K, Life Sci 2004 Jul 30;75(11):1333-41.
|
||